Can MRK’s New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE?
Merck MRK faces a looming patent cliff as its blockbuster PD-L1, Keytruda, approaches loss of exclusivity (LOE) in 2028. The drug...
Drugs
Merck MRK faces a looming patent cliff as its blockbuster PD-L1, Keytruda, approaches loss of exclusivity (LOE) in 2028. The drug...
